Win Ratio Analysis of Transvenous Phrenic Nerve Stimulation to Treat Central Sleep Apnoea in Heart Failure
This WR analysis of the remedē® System Pivotal Trial suggests that TPNS may be superior to untreated CSA in HF patients with CSA using a hierarchical clinical benefit endpoint composed of mortality, HF hospitalization, and health status.
Authors
- Olaf Oldenburg
- Maria Rosa Costanzo (ORCID: https://orcid.org/0000-0001-6995-7538)
- Piotr Ponikowski (ORCID: https://orcid.org/0000-0002-3391-7064)
- Rami Khayat (ORCID: https://orcid.org/0000-0003-4240-5754)
- Scott McKane (ORCID: https://orcid.org/0000-0002-2886-6864)
- Mitja Lainščak (ORCID: https://orcid.org/0000-0002-5922-4098)
- William T. Abraham (ORCID: https://orcid.org/0000-0003-4805-1037)
- Robin Germany (ORCID: https://orcid.org/0000-0001-5182-4745)
- Jerryll Asin (ORCID: https://orcid.org/0000-0002-9573-9478)
Institutions
- University of Ljubljana (SI)
- University of California, Irvine (US)
- Oklahoma City University (US)
- Wroclaw Medical University (PL)
- Pomurski muzej Murska Sobota (SI)
- University of California, Irvine Medical Center (US)
- Amphia Ziekenhuis (NL)
- Ludger (United Kingdom) (GB)
- University of Oklahoma Health Sciences Center (US)
- The Ohio State University (US)
- MRIGlobal (US)
- University of Oklahoma (US)
Publication Details
- Journal
- ESC Heart Failure
- Published
- 2024-10-18
- DOI
- https://doi.org/10.1002/ehf2.15074
- Citations
- 7
- Primary Topic
- Tracheal and airway disorders
- Type
- article
- Field-Weighted Citation Impact
- 2.93
Funders
- ZOLL Medical Corporation
- Respicardia